

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

Monday, April 28, 1997		
<i>Conference Overview</i>		
8:30 a.m. - 10:00 a.m. Session 1: Plenary Lectures	Opening Session: Overview of Immune-Deficiency Malignancies	Auditorium
10:00 a.m. - 10:30 a.m.	<i>Break</i>	
10:30 a.m. - 12:15 p.m. Session 2: Slide Presentation	Spectrum of Malignancies: Epidemiology	Auditorium
12:15 p.m. - 2:00 p.m.	<i>Lunch Break</i>	
2:00 p.m. - 3:15 p.m. Session 3: Plenary Lectures	Non-AIDS-Defining, HPV-Associated, and Pediatric Malignancies	Auditorium
3:15 p.m. - 3:45 p.m.	<i>Break</i>	
3:45 p.m. - 6:00 p.m. Session 4: Slide Presentations and Plenary Lectures	Non-AIDS-Defining, HPV, and Pediatric Cancers: Epidemiology & Clinical	Auditorium
8:00 a.m. - 7:30 p.m. Session 5: Poster Presentation 6:00-6:30 PM: <i>Authors stand by posters</i>	Kaposi's Sarcoma Abstract Numbers 12 - 66	Atrium & Lower Level Foyer

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

Tuesday, April 29, 1997 <i>Conference Overview</i>		
8:30 a.m. - 9:45 a.m. Session 6: Plenary Lectures	Kaposi's Sarcoma	Auditorium
9:45 a.m. - 10:15 a.m.	<i>Break</i>	
10:15 a.m. - 12:00 noon Session 7: Slide Presentations	Kaposi's Sarcoma: Pathogenesis	Auditorium
12:00 noon - 1:45 p.m.	<i>Lunch Break</i>	
1:45 p.m. - 3:55 p.m. Session 8: Plenary Lectures and Slide Presentations	Kaposi's Sarcoma: Clinical Investigations	Auditorium
3:55 p.m. - 4:15 p.m.	<i>Break</i>	
4:15 p.m. - 6:45 p.m. Session 9: Symposium and Slide Presentations	KSHV/HHV-8 Molecular Biology and Virology	Auditorium
8:00 a.m.- 8:00 p.m. Session 10: Poster Presentation 6:45-7:15 p.m.: <i>Authors stand by posters</i>	Non-Hodgkins Lymphoma and HPV-Associated Neoplasia Abstract Numbers 85 - 134	Atrium & Lower Level Foyer

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

Wednesday, April 30, 1997		
<i>Conference Overview</i>		
8:30 a.m. - 9:45 a.m. Session 11: Plenary Lectures	Non-Hodgkin's Lymphoma	Auditorium
9:45 a.m. - 10:15 a.m.	<i>Break</i>	
10:15 a.m. - 12:15 p.m. Session 12: Slide Presentations	Non-Hodgkin's Lymphoma: Molecular Biology, Immunology, and Animal Models	Auditorium
12:15 p.m. - 1:15 p.m.	<i>Lunch Break</i>	
1:15 p.m. - 2:45 p.m. Session 13: Slide Presentations	Non-Hodgkin's Lymphoma: Herpes Viruses	Auditorium
2:45 p.m. - 4:00 p.m. Session 14: Plenary Lectures and Slide Presentations	Non-Hodgkin's Lymphoma: Therapy	Auditorium

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

Monday, April 28, 1997	
Session 1. Opening Session: Overview of Immune-Deficiency Malignancies 8:30 a.m. - 10:00 a.m. <i>Auditorium</i>	
8:30 a.m.	Opening Remarks and Welcome <i>ELLEN G. FEIGAL, Chair, Scientific Program Committee, National Cancer Institute</i> <i>JAMES J. GOEDERT, Co-Chair, Scientific Program Committee, National Cancer Institute</i> AIDS Malignancy: The NCI Perspective <i>RICHARD KLAUSNER, Director, National Cancer Institute</i>
Plenary Lectures	

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

8:45 a.m.	S1: Overview of the Epidemiology of Immune-Deficiency Malignancies <i>VALERIE BERAL, University of Oxford</i>
9:10 a.m.	S2: Viral-Mediated Mechanisms of Cancer Pathogenesis <i>ELLIOTT KIEFF, Harvard University</i>
9:35 a.m.	S3: HPV-Related Malignancies <i>JOEL PALEFSKY, University of California, San Francisco</i>
10:00 a.m.	<i>BREAK</i>

Monday, April 28, 1997

Session 2. Slide Presentations:

Spectrum of Malignancies: Epidemiology

10:30 a.m. - 12:15 p.m.

Auditorium

Moderators:

ROBERT BIGGAR, National Cancer Institute

HAROLD JAFFE, Centers for Disease Control and Prevention

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

10:30 a.m.	1: Risk Factors for HHV-8 Seropositivity and Progression to Kaposi's Sarcoma in a Cohort of Homosexual Men, 1981-96 <i>MADS MELBYE, Danish Epidemiology Science Centre, Copenhagen, Denmark</i>
10:45 a.m.	2: Route of Transmission of Kaposi's Sarcoma-Associated Herpesvirus <i>ANDREW GRULICH, National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia</i>
11:00 a.m.	3: Risk Factors for HIV-Related Malignancies in Children <i>BRAD H. POLLOCK, University of Florida College of Medicine</i>
11:15 a.m.	4: Non-Hodgkin's Lymphoma in HIV+ and HIV- Men in the San Francisco Bay Area: Allergies, Prior Medication Use, and Sexual Practices <i>ELIZABETH A. HOLLY, University of California, San Francisco</i>
11:30 a.m.	5: A Review of the Aetiology of Squamous Cell Carcinoma of the Conjunctiva, with Preliminary Results of a Case-Control Study from Kampala, Uganda <i>ROBERT NEWTON, University of Oxford</i>
11:45 a.m.	6: Abnormal Cervical Cytology in HIV-Infected Women <i>RACHEL G. FRUCHTER, State University of New York Health Science Center at Brooklyn</i>

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

12:00 Noon	SL1: AIDS Malignancies: The Community Perspective <i>MICHAEL MARCO, Treatment Action Group</i>
12:15 p.m.	<i>LUNCH BREAK</i>

Monday, April 28, 1997	
Session 3. Plenary Lectures: Non-AIDS-Defining, HPV-Associated, and Pediatric Malignancies 2:00 p.m. - 3:15 p.m. <i>Auditorium</i>	
Moderators: <i>JOEL PALEFSKY, University of California, San Francisco</i> <i>PHILIP PIZZO, Harvard Medical School, Children's Hospital, Boston</i>	
2:00 p.m.	S4: Epidemiology of Non-AIDS-Defining Malignancies in HIV <i>CHARLES RABKIN, National Cancer Institute</i>
2:25 p.m.	S5: HPV and Cervical Cancer from Pathogenesis to Prevention <i>DOUGLAS LOWY, National Cancer Institute</i>
2:50 p.m.	S6: Malignancies in HIV-Infected Children <i>BRIGITTA U. MUELLER, Harvard Medical School, Children's Hospital, Boston</i>
3:15 p.m.	<i>BREAK</i>

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

Monday, April 28, 1997

Session 4. Slide Presentations and Plenary Lectures:

Non-AIDS-Defining, HPV, and Pediatric Cancers: Epidemiology & Clinical

3:45 p.m. - 5:45 p.m.

Auditorium

Moderators:

JOEL PALEFSKY, University of California, San Francisco

PHILIP PIZZO, Harvard Medical School, Children's Hospital, Boston

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

3:45 p.m.	7: Risk Factors for Childhood Kaposi's Sarcoma in Uganda: A Case-Control Study <i>S.M. MBULAITETE, Uganda Cancer Institute, Kampala, Uganda</i>
4:00 p.m.	8: Rates of Non-AIDS-Defining Cancers in People with AIDS <i>ANDREW GRULICH, National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia</i>
4:15 p.m.	9: The Ten-Year Cancer and HIV Experience of the University of Medicine and Dentistry of New Jersey-University Hospital Cancer Registry: Excess Proportions of Hodgkin's Lymphoma and Lung Cancer <i>STANLEY H. WEISS, University of Medicine and Dentistry of New Jersey- New Jersey Medical School</i>
4:30 p.m.	10: Intraepithelial Neoplasia of the Anogenital Area in HIV-Infected Homosexual Men <i>MARGARET MULDROW, Denver Department of Health</i>
4:45 p.m.	11: HIV Infection and Associated Immunosuppression Accelerates Progression of HPV-Related Cervical Neoplasia in Injection Drug-Using Women <i>LINDA AHDIEH, Johns Hopkins School of Public Health</i>
Session 4: Plenary Lectures	

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

5:00 p.m.	S7: Hodgkin's Disease <i>ALEXANDRA M. LEVINE, University of Southern California School of Medicine, Norris Cancer Hospital and Research Institute</i>
5:30 p.m.	S8: Cervical Cancer in HIV-Infected Women <i>MITCHELL MAIMAN, State University of New York Downstate Medical School</i>

Monday, April 28, 1997	
Session 5. Poster Presentations: Kaposi's Sarcoma 8:00 a.m. - 7:30 p.m. Atrium & Lower Level Foyer	
6:00 p.m. - 6:30 p.m.	Abstract Numbers 12 - 66 <i>Authors Stand by Posters</i>

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

Tuesday, April 29, 1997	
Session 6. Plenary Lectures:	
Kaposi's Sarcoma	
8:30 a.m. - 9:45 a.m.	
<i>Auditorium</i>	
Moderator:	
<i>PARKASH S. GILL, University of Southern California School of Medicine, Norris Cancer Hospital and Research Institute</i>	
8:30 a.m.	S9: KSHV/HHV-8 <i>ROBIN WEISS, The Institute of Cancer Research, Royal Cancer Hospital, Chester Beatty Laboratories, London, United Kingdom</i>
8:55 a.m.	S10: Cytokines and Pathogenesis <i>ROBERT GALLO, Institute of Human Virology, University of Maryland Medical Center</i>
9:20 a.m.	S11: Angiogenesis <i>JUDAH FOLKMAN, Harvard Medical School</i>
9:45 a.m.	<i>BREAK</i>

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

Tuesday, April 29, 1997
Session 7. Slide Presentations: Kaposi's Sarcoma: Pathogenesis 10:15 a.m. - 12:00 noon <i>Auditorium</i>
Moderator: <i>ROBERT YARCHOAN, National Cancer Institute</i>

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

10:15 a.m.	67: Vascular Endothelial Growth Factor/Vascular Permeability Factor is an Autocrine Growth Factor for AIDS-Kaposi's Sarcoma <i>RIZWAN MASOOD, University of Southern California</i>
10:30 a.m.	68: HIV-1 Tat Protein Enhances Angiogenesis and Kaposi's Sarcoma Development Triggered by Inflammatory Cytokines or -Fibroblast Growth Factor by Engaging the v3 Integrin <i>GIOVANNI BARILLARI, University "Tor Vergata," Rome, Italy</i>
10:45 a.m.	69: Activation of HHV-8 (KSHV) by HIV-1 Tat <i>WILLIAM J. HARRINGTON, JR., Sylvester Cancer Center</i>
11:00 a.m.	70: Th-1 Cytokine Profile in Peripheral Blood Mononuclear Cells and Tumor Infiltrating Lymphocytes of HHV-8 Kaposi's Sarcoma Patients: Role of -Interferon in Kaposi's Sarcoma Development (An Immune Response to HHV-8) <i>BARBARA ENSOLI, Istituto Superiore di Sanità, Rome, Italy</i>
11:15 a.m.	71: <i>In Situ</i> Detection of Kaposi's Sarcoma Herpesvirus/Human Herpesvirus-8 and Expression of the Cyclin D Homolog in Early Patch-Stage Lesions of Kaposi's Sarcoma <i>JON A. REED, New York Hospital/Cornell Medical Center</i>
11:30 a.m.	72: Isolation of Human Herpesvirus-8 from Peripheral Blood Mononuclear Cells of AIDS-Kaposi's Sarcoma Patients and Viral Transmission to Primary Cell Culture <i>SANDRA COLUMBINI-HATCH, University of Maryland Biotechnology Institute</i>

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

11:45 a.m.	73: Host Range Studies of Human Herpesvirus-8 <i>DAVID A. BLACKBOURN, University of California, San Francisco</i>
12:00 noon	<i>LUNCH BREAK</i>

Tuesday, April 29, 1997	
Session 8. Plenary Lecture and Slide Presentations: Kaposi's Sarcoma: Clinical Investigations 1:45 p.m. - 3:55 p.m. Auditorium	
Moderator: <i>SUSAN E. KROWN, Memorial Sloan-Kettering Cancer Center</i>	
1:45 p.m.	S12: Clinical Overview of Kaposi's Sarcoma Treatment <i>SUSAN E. KROWN, Memorial Sloan-Kettering Cancer Center</i>
Abstracts	

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

2:10 p.m.	74: Analysis of Human Herpesvirus-8 Infection in Children and Adults by Measuring Serum Antibodies to a Peptide of a Minor Capsid Protein or by Polymerase Chain Reaction <i>RACHEL W. HUMPHREY, National Cancer Institute</i>
2:25 p.m.	75: Primary Human Herpesvirus Type 8 Infection Occurs Following Adolescence in the United States <i>ANDREW BLAUVELT, National Cancer Institute</i>
2:40 p.m.	76: A Phase II Study of Thalidomide for Kaposi's Sarcoma: Activity and Correlation with KSHV DNA Load <i>MARK BOWER, Charing Cross Hospital, London, United Kingdom</i>
2:55 p.m.	77: Low Dose Paclitaxel (TAXOL®) is Highly Effective in the Treatment of Patients with Advanced AIDS-Related Kaposi's Sarcoma <i>PARKASH S. GILL, University of California School of Medicine, Norris Cancer Hospital and Research Institute</i>
3:10 p.m.	78: Fumagillin Analog (TNP-470) in the Treatment of Kaposi's Sarcoma: A Phase I AIDS Clinical Trial Group Study <i>BRUCE DEZUBE, Beth Israel Deaconess Medical Center</i>
3:25 p.m.	79: Evidence of Activity of Vinorelbine in Patients with Previously Treated Epidemic Kaposi's Sarcoma <i>MICHELE SPINA, Centro di Riferimento Oncologico, Aviano, Italy</i>

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

3:40 p.m.	80: Relationship of HHV-8 Peripheral Blood Mononuclear Cell Burden to Immunodeficiency, Opportunistic Infections, Response to Therapy, and Stage of Kaposi's Sarcoma <i>DAVID J. LOONEY, University of California, San Diego</i>
3:55 p.m.	<i>BREAK</i>

Tuesday, April 29, 1997

Session 9. Symposium and Slide Presentations:

KSHV/HHV-8 Molecular Biology and Virology

4:15 p.m. - 6:45 p.m.

Auditorium

Moderator:

PATRICK S. MOORE, Columbia University

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

4:15 p.m.	S13: KSHV-Encoded Oncogenes and Oncogenesis <i>PATRICK S. MOORE, Columbia University</i>
4:35 p.m.	S14: Human Herpesvirus-8 - the Causative Agent of Kaposi's Sarcoma <i>BERNHARD FLECKENSTEIN, University of Erlangen-Nuernberg, Germany</i>
4:50 p.m.	S15: Latent and Lytic Replication of HHV-8/KSHV <i>DONALD GANEM, University of California, San Francisco</i>
5:10 p.m.	S16: Novel Features of the Genome of KSHV/HHV-8 <i>GARY HAYWARD, Johns Hopkins University School of Medicine</i>
Abstracts Moderator: <i>PATRICK S. MOORE, Columbia University</i>	

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

5:45 p.m.	81: Lack of Expression of the Viral IL-6 Homologue in KSHV-Associated Tumors <i>JENNIFER SHEAFFER, Johns Hopkins University School of Medicine</i>
6:00 p.m.	82: Characterization of Kaposi's Sarcoma-Associated Herpesvirus Cyclin <i>MENGTAO LI, Harvard Medical School</i>
6:15 p.m.	83: Anti-Apoptotic BCL-2 Homologs Encoded by Kaposi's Sarcoma Associated Virus and Herpesvirus Saimiri; A Role During Virus Infections <i>J. MARIE HARDWICK, Johns Hopkins School of Public Health</i>
6:30 p.m.	84: KSHV/HHV-8 Encodes a Constitutively Active G Protein-Coupled Receptor Linked to Cell Proliferation <i>LEANDROS ARVANITAKIS, Cornell University Medical College</i>

Tuesday, April 29, 1997

Session 10. Poster Presentations:

Non-Hodgkin's Lymphoma and HPV-Associated Neoplasia

8:00 a.m.- 8:00 p.m.

Atrium & Lower Level Foyer

6:45 p.m. - 7:15 p.m.

Abstract Numbers 85 - 134

Authors Stand by Posters

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

Wednesday, April 30, 1997	
Session 11. Plenary Lectures: Non-Hodgkin's Lymphoma 8:30 a.m. - 9:45 a.m. Auditorium	
Moderator: <i>RICCARDO DALLA FAVERA, Columbia University</i>	
8:30 a.m.	S17: The Role of Herpesviruses in Immune Deficiency-Associated Lymphomas <i>ALAN RICKINSON, University of Birmingham, United Kingdom</i>
8:55 a.m.	S18: Immunotherapy for EBV-Associated Lymphoproliferative Disease <i>CLIONA M. ROONEY, St. Jude Children's Research Hospital</i>
9:20 a.m.	S19: Molecular Mechanisms of Pathogenesis <i>RICCARDO DALLA FAVERA, Columbia University</i>
9:45 a.m.	<i>BREAK</i>

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

Wednesday, April 30, 1997
Session 12. Slide Presentations: Non-Hodgkin's Lymphoma: Molecular Biology, Immunology, and Animal Models 10:15 a.m. - 12:15 p.m. Auditorium
Moderator: <i>DAVID SCADDEN, Harvard Medical School</i>

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

10:15 a.m.	135: Clonal HIV is Present in a Wide Variety of HIV-Associated Malignancies, and Cell Separation Studies Map the Clone to Tumor-Associated Macrophages <i>BRUCE SHIRAMIZU, University of California, San Francisco</i>
10:30 a.m.	136: Correlative Morphologic and Molecular Genetic Analysis of 75 AIDS- Related Systemic Non-Hodgkin's Lymphomas <i>ROLAND G. NADOR, New York Hospital/Cornell Medical Center</i>
10:45 a.m.	137: Genetic Alterations and Expression Status of <i>BCL-6</i> in AIDS-Related Lymphomas: Relationship with EBV Infection and Identification of Distinct Molecular Pathways in AIDS-Lymphomagenesis <i>GIANLUCA GAIDANO, University of Torino at Novara, Italy</i>
11:00 a.m.	138: Skewed and Unstable B-Cell Repertoire in Serial Blood Samples of HIV- Infected Patients. Potential Role in the Induction of AIDS-Associated Lymphoma <i>ALBERTO BESSUDO, University of California, San Diego Cancer Center</i>
11:15 a.m.	139: Evidence for Signal Transduction Through the Tumor Necrosis Family Receptor Pathway in Post-Transplant Lymphoproliferative Disorders <i>DAVID LIEBOWITZ, University of Chicago</i>
11:30 a.m.	140: Functional Analysis of the Tumor Suppressor Gene P53 in Non-Hodgkin's Lymphomas and Atypical Lymphoproliferative Disorders Related to AIDS <i>RAPHAEL MARTINE, Hematology Hôpital Avicenne, Bobigny, France</i>

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

11:45 a.m.	141: Lymphoma Development in Simian Immunodeficiency Virus-Infected Monkeys <i>PETER BIBERFELD, Karolinska Institute and Hospital, Stockholm, Sweden</i>
12:00 noon	142: Cytokine Gene Transcription and Growth Regulation of B-NHL in Simian Immunodeficiency Virus-Infected Monkeys <i>CHRISTIAN BUSKE, University of Goettingen Hospital, Goettingen, Germany</i>
12:15 p.m.	<i>LUNCH BREAK</i>

Wednesday, April 30, 1997

Session 13. Slide Presentations:

Non-Hodgkin's Lymphoma: Herpes Viruses

1:15 p.m. - 2:45 p.m.

Auditorium

Moderator:

RICHARD AMBINDER, Johns Hopkins Oncology Center

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

1:15 p.m.	143: The Spectrum of Lymphomas Containing KSHV/HHV-8 <i>DANIEL M. KNOWLES, New York Hospital/Cornell Medical Center</i>
1:30 p.m.	144: Cytokinesis of AIDS-Associated Primary Effusion Lymphomas <i>SERHAN ALKAN, Loyola University Medical Center</i>
1:45 p.m.	145: EBV-DNA in CSF as a Marker for Non-Invasive Diagnosis of AIDS-Related Primary Central Nervous System Lymphoma <i>ANTONELLA CINGOLANI, Catholic University, Rome, Italy</i>
2:00 p.m.	146: Reversal of Malignant Cell Growth Phenotype by Hydroxyurea-Induced Loss of Epstein-Barr Virus Episomes <i>KAREN SLOBOD, St. Jude Children's Research Hospital</i>
2:15 p.m.	147: Adoptive Immunotherapy Using Autologous EBV-Specific Cytotoxic T Lymphocytes in an HIV-Infected Patient with Refractory Epstein-Barr Virus-Expressing B-Cell Lymphoma <i>GRAYSON H. WHEATLEY, III, Duke University Medical Center</i>
2:30 a.m.	148: Antisense Gene Therapy Directed Against EBNA-1 in EBV-Associated B- Cell Lymphomas Results in Potentiation of Chemotherapy in Vitro and Decreased Tumor Virulence in SCID Mice <i>MYRA B. MORGAN, University of Colorado Health Sciences Center</i>

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

Wednesday, April 30, 1997
Session 14. Plenary Lectures and Slide Presentations: Non-Hodgkin's Lymphoma: Therapy 2:45 p.m. - 4:00 p.m. Auditorium
Moderator: <i>ALEXANDRA M. LEVINE, University of Southern California School of Medicine</i>

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

2:45 p.m.	S20: Treatment of HIV Non-Hodgkin's Lymphoma, A Clinical Overview <i>LAWRENCE D. KAPLAN, San Francisco General Hospital</i>
3:15 p.m.	149: Therapy of HIV-Related Non-Hodgkin's Lymphoma: A European Multicentric Randomized Study in Patients Stratified According to Their Prognostic Factors: Preliminary Results <i>CHRISTIAN GISSELBRECHT, Institute d'Hématologie Hôpital St. Louis, Paris, France</i>
3:30 p.m.	150: Results of a Treatment Protocol for Children with HIV and Non-Hodgkin's Lymphomas <i>AZIZA SHAD, Georgetown University Medical Center</i>
3:45 p.m.	151: Is Lymphocytic Interstitial Pneumonitis an Early Stage of MALT Lymphoma in HIV-Infected Pediatric Patients? <i>JULIE TERUYA-FELDSTEIN, National Cancer Institute</i>

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

Program Chairs and Committee Members

Program Chair	Program Co-Chair
<p>Dr. Ellen G. Feigal <i>Senior Investigator</i> <i>Cancer Therapy Evaluation Program</i> <i>Division of Cancer Treatment,</i> <i>Diagnosis and Centers</i> <i>National Cancer Institute</i> <i>Bethesda, Maryland</i></p>	<p>Dr. James J. Goedert <i>Chief, Viral Epidemiology Branch</i> <i>Division of Cancer Epidemiology</i> <i>and Genetics</i> <i>National Cancer Institute</i> <i>Bethesda, Maryland</i></p>

Program Committee		
<p>Dr. Richard Ambinder <i>Associate Professor of Oncology</i> <i>Johns Hopkins Oncology Center</i> <i>Baltimore, Maryland</i></p>	<p>Dr. Robert Biggar <i>International AIDS Coordinator</i> <i>Viral Epidemiology Branch</i> <i>Division of Cancer Epidemiology</i> <i>and Genetics</i> <i>National Cancer Institute</i> <i>Bethesda, Maryland</i></p>	<p>Dr. Riccardo Dalla Favera <i>Professor of Pathology</i> <i>Department of Pathology</i> <i>Columbia University</i> <i>New York, New York</i></p>

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

<p>Dr. Parkash S. Gill <i>Professor of Medicine and Pathology</i> <i>University of Southern California</i> <i>School of Medicine</i> <i>Norris Cancer Hospital</i> <i>and Research Institute</i> <i>Los Angeles, California</i></p>	<p>Mr. Mark Harrington <i>Policy Director</i> <i>Treatment Action Group</i> <i>New York, New York</i></p>	<p>Dr. Elaine Jaffe <i>Chief, Hematopathology Section</i> <i>Laboratory of Pathology</i> <i>Division of Clinical Sciences</i> <i>National Cancer Institute</i> <i>Bethesda, Maryland</i></p>
<p>Dr. Harold Jaffe <i>Associate Director for HIV/AIDS</i> <i>National Center for Infectious Diseases</i> <i>Centers for Disease Control and Prevention</i> <i>Atlanta, Georgia</i></p>	<p>Dr. Elliott Kieff <i>Professor of Microbiology and Molecular Genetics</i> <i>Infectious Disease Division</i> <i>Channing Labs</i> <i>Brigham and Women's Hospital</i> <i>Professor of Medicine</i> <i>Harvard University</i> <i>Boston, Massachusetts</i></p>	<p>Dr. Alexandra M. Levine <i>Professor of Medicine</i> <i>University of Southern California</i> <i>School of Medicine</i> <i>Norris Cancer Hospital</i> <i>and Research Institute</i> <i>Los Angeles, California</i></p>

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

<p>Mr. Michael Marco <i>Director, Opportunistic Diseases Treatment Action Group New York, New York</i></p>	<p>Dr. Patrick S. Moore <i>Associate Professor School of Public Health Columbia University New York, New York</i></p>	<p>Dr. Joel Palefsky <i>Associate Professor of Laboratory Medicine Department of Laboratory Medicine University of California, San Francisco San Francisco, California</i></p>
<p>Dr. Philip Pizzo <i>Thomas Morgan Rotch Professor and Chair Department of Pediatrics Harvard Medical School Physician-In-Chief Department of Medicine Children's Hospital Boston, Massachusetts</i></p>	<p>Dr. David Scadden <i>Associate Professor of Medicine Harvard Medical School Massachusetts General Hospital Boston, Massachusetts</i></p>	<p>Dr. Gene Shearer <i>Chief, Cell Mediated Immunity Section Division of Basic Sciences National Cancer Institute Bethesda, Maryland</i></p>
	<p>Dr. Robert Yarchoan <i>Chief, HIV and AIDS Malignancy Branch Division of Clinical Sciences National Cancer Institute Bethesda, Maryland</i></p>	

The National AIDS Malignancy Conference

April 28 - 30, 1997

FINAL CONFERENCE PROGRAM

CME/AMA Accreditation

The NIH/FAES is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The NIH/FAES designates this educational activity for a maximum of 25 hours in category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

15 April 1997